THRD - Third Harmonic Bio Inc.

https://www.thirdharmonicbio.com

Hold Momentum: Bearish

Recent News

Third Harmonic Bio Stock Is Up 40% Monday: What's Happening? - Third Harmonic Bio ( NASDAQ:THRD )

Third Harmonic Bio's board approves and adopts a plan for the liquidation and dissolution of the company. The company estimates total shareholder distributions in the range of $246.6 million to $259.8 million, or $5.13 to $5.42 per share. Feel unsure about the market's next move?

Bullish

Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire • 5 months, 2 weeks ago • score: 0.21

Recently presented THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria ...

Bullish

Third Harmonic Bio, Inc. ( THRD ) Loses -31.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Commentary • 6 months, 1 week ago • score: 0.24

The heavy selling pressure might have exhausted for Third Harmonic Bio, Inc. (THRD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...

Bullish

Third Harmonic Bio, Inc. ( THRD ) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Commentary • 7 months ago • score: 0.38

Third Harmonic Bio, Inc. (THRD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Bullish

Down -39.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Third Harmonic Bio, Inc. ( THRD )

Zacks Commentary • 7 months ago • score: 0.24

Bullish

Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape - Third Harmonic Bio ( NASDAQ:THRD )

Benzinga • 7 months ago • score: 0.34

THB335 showed dose-dependent serum tryptase reductions from 13% to 84% at Day 15, supporting its advancement to Phase 2 in CSU. Third Harmonic Bio will halt non-THB335 research and cut 50% of its workforce while reviewing strategic options.

Bearish

Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - NeuroPace ( NASDAQ:NPCE ) , Cogent Biosciences ( NASDAQ:COGT )

Benzinga • 8 months, 1 week ago • score: -0.59

U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 0.1% on Tuesday. Shares of Acelyrin, Inc. SLRN fell sharply in today's pre-market trading. ACELYRIN announced additional Phase 2 data and the Phase 3 program design for lonigutamab in Thyroid Eye Disease.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-09 (Snapshot)

None

52W High

$16.02

52W Low

$3.18

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

2.13

Valuation

As of 2025-03-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-2.09

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

0.89

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

9.11%

Institutions (25–75% balanced)

80.12%

Shares Outstanding

45,127,800

Float

15,603,400

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-03-31 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-1.24

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.20%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.0021

-0.0022

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025